Company news

AbCellera Biologics Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients

March 4, 2021

AbCellera to Present at the SVB Leerink Global Healthcare Conference

February 16, 2021

AbCellera Appoints Ester Falconer, Ph.D., as Chief Technology Officer

February 10, 2021

AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19

February 8, 2021

AbCellera Announces Date of Fourth Quarter 2020 Financial Results Conference Call

February 2, 2021

AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19

January 26, 2021

AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70%

January 25, 2021

AbCellera-Discovered Antibody Prevented COVID-19 in Nursing Homes and Reduced Risks by up to 80% for Residents

January 20, 2021

AbCellera Granted U.S. Patent Covering its Trianni Mouse® Technology

January 18, 2021

AbCellera-Discovered Neutralizing Antibody for COVID-19 Enters New Pragmatic Study in New Mexico

December 20, 2020

AbCellera Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

December 14, 2020

AbCellera Announces Pricing of Initial Public Offering

December 9, 2020

← Newer news releases

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 39 decks. Every deck is listed under its year.